WP
ELVN icon

Woodline Partners’s Enliven Therapeutics ELVN Stock Holding History

Woodline Partners’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.6M Buy
347,142
+45,469
+15% +$1.93M 0.05% 396
2026
Q1 		$11.8M Buy
301,673
+650
+0.2% +$18K 0.04% 469
2025
Q4 		$4.64M Buy
301,023
+524
+0.2% +$10.4K 0.02% 636
2025
Q3 		$6.15M Sell
300,499
-800,158
-73% -$16.1M 0.03% 525
2025
Q2 		$22.1M Buy
1,100,657
+295,500
+37% +$5.59M 0.12% 259
2025
Q1 		$15.8M Sell
805,157
-765
-0.1% -$16.5K 0.1% 266
2024
Q4 		$18.1M Sell
805,922
-265
-0% -$6.87K 0.12% 227
2024
Q3 		$20.6M Buy
806,187
+83,683
+12% +$1.94M 0.17% 189
2024
Q2 		$16.9M Buy
722,504
+326,818
+83% +$6.88M 0.16% 189
2024
Q1 		$6.96M Hold
395,686
– – 0.06% 322
2023
Q4 		$5.48M Hold
395,686
– – 0.06% 308
2023
Q3 		$5.41M Buy
+395,686
New +$6.66M 0.06% 304
2023
Q1 		– Sell
-216,601
Closed -$3.54M – 676
2022
Q4 		$3.54M Hold
216,601
– – 0.05% 373
2022
Q3 		$1.98M Sell
216,601
-21,222
-9% -$125K 0.03% 462
2022
Q2 		$1.16M Sell
237,823
-18,431
-7% -$90.1K 0.02% 501
2022
Q1 		$1.93M Buy
256,254
+183,645
+253% +$1.21M 0.03% 397
2021
Q4 		$653K Buy
72,609
+39,068
+116% +$512K 0.01% 540
2021
Q3 		$547K Buy
+33,541
New +$697K 0.01% 544

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Woodline Partners's ELVN Position: Q2 2026 in Review

Woodline Partners increased its Enliven Therapeutics (ELVN) stake by 15% in Q2 2026, buying an estimated $1.93M and bringing the position to 347,142 shares worth $17.6M. The position accounts for 0.05% of the portfolio, ranked #396.

Woodline Partners first reported a position in ELVN in Q3 2021 and has held it in 18 quarters since. The position peaked at $22.1M in Q2 2025. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Woodline Partners held 347,142 shares of Enliven Therapeutics worth $17.6M as of Q2 2026.
  • Woodline Partners bought 45,469 Enliven Therapeutics shares in Q2 2026, an estimated $1.93M.
  • Enliven Therapeutics made up 0.05% of Woodline Partners's portfolio in Q2 2026, its #396 holding.
  • Woodline Partners first reported a position in Enliven Therapeutics in Q3 2021 and has held it in 18 quarters since.
  • Woodline Partners's Enliven Therapeutics position peaked at $22.1M in Q2 2025.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.